The Centers for Disease Control and Prevention (CDC) today announced a change in its guidance regarding using Nirsevimab (Beyfortus™) in a Clinician Outreach and Communication Activity email.
As of January 5, 2023, the CDC says that infants and children recommended to receive Beyfortus should be immunized as quickly as possible.
Immunize Infants with Beyfortus As Quickly As Possible
Mass Vaccinations Target Brazil's Dengue Outbreak
Throughout 2023, the Pan American Health Organization (PAHO) reported significant increases in the number of dengue virus cases. By mid-December, the Region had experienced about 57% increase in dengue cases compared with data published in 2022.
And the Region experienced a case fatality rate of 0.049%.
The ongoing dengue outbreak has significantly impacted the Federative Republic of Brazil, which confirmed over 1.6 million dengue cases in 2023.
Nirmatrelvir During Acute SARS-CoV-2 Does Not Reduce Risk for Long COVID
No association seen for rebound symptoms or test positivity with symptoms of long COVID